As a major cause of acute and chronic liver disease as well as hepatocellular carcinoma, hepatitis B virus (HBV) continues to pose significant health problems worldwide. Recombinant hepatitis B vaccines based on adenovirus vectors have been developed to address global needs for effective control of hepatitits B infection. Although considerable progress has been made in the construction ofrecombinant adenoviruses that express large amounts of HBV gene products, preclinical immunogenicity and efficacy testing of candidate vaccines has remained difficult due to the lack of a suitable animal model. We demonstrate here that chimpanzees are susceptible to enteric infection by human adenoviruses type 7 (Ad7) and type 4 (Ad4) following oral admiistrtion of live virus. Moreover, after sequential oral immunization with Ad7-and Ad4-vectored vaccines containing the hepatitis B surface antigen (HBsAg) gene, significant antibody responses to HBsAg (anti-HBs) were induced in two chimpanzees. After challenge with heterologous HBV, one chimpanzee was protected from acute hepatitis and the other chimpanzee experienced modified HBV-induced disease. These data demonstrate the feasibility of using orally administered recombinant adenoviruses as a general approach to vaccination.
Hepatitis B is a serious health problem worldwide that afflicts more than 300 million individuals, with 0.5-1 million new cases appearing annually in China alone (1, 2) . To address the requirements for an inexpensive, effective, and easily administered hepatitis B vaccine, live recombinant hepatitis B vaccines using adenovirus vectors have been developed. The adenovirus vector approach is based, in part, on the successful application during the past 2 decades of live adenovirus vaccines for prevention of acute respiratory disease in military trainees (3, 4) . Selective infection of the intestine with orally administered adenovirus types 4 and 7 (Ad4 and Ad7) vaccines has been highly effective in suppression of acute respiratory disease in military recruits, which is caused primarily by these two adenovirus serotypes.
Experimental adenovirus-vectored hepatitis B vaccines have been described (5) (6) (7) (8) , but preclinical testing of these vaccines in animals has been difficult due to the highly restricted host range of human adenoviruses. Although models for disease induced by adenoviruses have been sought since their discovery over 3 decades ago, only recently have the cotton rat (9) and the hamster (7, 10) been identified as models for adenovirus-induced respiratory infections. Although these rodent species support lung replication of various adenovirus serotypes, these animals are not susceptible to infections by Ad4 or Ad7 (ref. 9; unpublished data), which, because of their wide prior usage, are good candidates as vectors. Other less well-characterized small animal models for human adenoviruses have been occasionally reported (11) (12) (13) but are likewise nonpermissive for Ad4 and Ad7 infections (unpublished data). An early study of animal species including nonhuman primates indicated that human adenoviruses do not induce acute respiratory disease in monkeys or chimpanzees following intranasal inoculations (14) . Serological data, however, indicated that such experimental infections occasionally induced anti-adenovirus antibodies in chimpanzees but not in monkeys.
In the present study, chimpanzees were evaluated for enteric infection by Ad4 and Ad7. We 
MATERIALS AND METHODS
Cells and Viruses. Cell line A549 derived from human lung carcinoma was used for calcium phosphate transfection as described (6) . The vaccine strains of Ad4 (CL68578) and Ad7 (55142) and the recombinant adenoviruses described below were grown and titrated on A549 cells as well as on the human diploid cell strain WI-38 (15) .
Construction of Recombinant Viruses. The recombinant adenoviruses described here were constructed by the same methods used to construct the recombinant adenovirus type 5 viruses previously described (6) . The HBsAg gene (extending from nucleotide 130 to 966; adw2 subtype) was inserted into a cloned fragment of the Ad7 genome that extended from Ad7 map unit (m.u.) 68 to m.u. 100, as shown in Fig. 1 (16) . When this recombinant plasmid was transfected into A549 cells together with Ad7 DNA, the recombinant virus Wy-Ad7HZ6-1 was generated by homologous recombination (Fig. 1) . HBsAg was secreted into the medium by cells infected with Wy-Ad7HZ6-1 and was found to consist of spherical particles (predominantly [20] [21] [22] [23] [24] [25] . Entericcoated capsules containing Ad7 and Wy-Ad4HHxHS were prepared as described above except that viruses were obtained directly from infected cell lysates. Capsules prepared from Wy-Ad4HHxHS-infected cell lysates contained <400 ng of HBsAg. After inoculation of chimpanzees, unused capsules were titrated following solubilization of lyophilized material in phosphate-buffered saline.
Chimpanzee Inoculations. Chimpanzee immunogenicity and challenge studies were conducted at Sema (Rockville, MD). Three males (nos. 1373, 1374, and 1376) and one female (no. 1375) 1-2 years old were selected for use in the study based on an adenovirus antibody screen (see Results). The chimpanzees were housed in individual isolators throughout the study and were maintained as described (18) . Prior to vaccination, a preliminary study was conducted to evaluate dissolution in the chimpanzee gut of enteric-coated capsules containing barium sulfate (capsules were prepared as indicated above). Serial roentgenograms indicated that the capsules disintegrated in the small or large bowel within 24 hr of capsule administration. For primary and booster immunizations, chimpanzees were given one or two enteric-coated capsules through a gastric tube after anesthetization with ketamine. Two hours after booster vaccinations, the chimpanzees were given 60 ml of0.10 M phosphate buffer (pH 8.0) to promote dissolution of the enteric-coated capsules in the chimpanzee gut. Seven weeks after booster inoculations, the three vaccinated chimpanzees and a control chimpanzee (no. 1376) received an intravenous challenge with 103-5 50% chimpanzee infectious units of HBV (subtype ayw, strain MS-2) (18).
Detection of Shed Virus. Stool samples were made 10%o (vol/vol) in Dulbecco's modified essential medium containing 2% penicillin/streptomycin and clarified by centrifugation prior to inoculation on A549 cell monolayers. Cultures not displaying adenovirus cytopathic effect by 10 days postinoculation were given a single blind passage and observed for an additional 10-day period. The presence of adenovirus antigen in cell culture fluids was confirmed by a monoclonal antibody-based enzyme linked immunosorbent assay (19) . The rabbit anti-Ad2 hexon antiserum and anti-Ad3 hexon monoclonal antibody (20/11 MAF) used in this assay were gifts of John C. Hierholzer (Centers for Disease Control, Atlanta, GA). Isolates were identified as adeno-hepatitis recombinants by evaluation of infected-cell culture fluids for HBsAg by RIA (Ausria II-125). After booster inoculations, the Ad4 serotype of adenovirus isolates was confirmed by neutralization analysis using type-specific polyclonal rabbit antisera.
Serology. Chimpanzees were bled at weekly intervals and sera were tested for anti-HBs antibodies by RIA (Ausab, Abbott). Anti-HBs responses are expressed in milliinternational units (mIU), based on a conversion factor of 3.5 RIA units per 1 mIU). Sera were further tested for HBsAg by RIA (Ausria 11-125), for anti-HBc (HBV core antigen) antibodies by a competition RIA (Corab, Abbott), alanine aminotransaminase (ALT) (20) , and anti-adenovirus antibodies by microneutralization analysis on A549 cell monolayers using a challenge dose of 30-100 50% tissue culture infectivity doses (8) .
RESULTS
Seroprevalence Study in Chimpanzees. Sera from 31 chimpanzees were screened for type-specific neutralizing antibodies to human Ad4 and Ad7. Although these chimpanzees were generally seronegative for anti-Ad7 antibodies (reciprocal titers, <4), 77% of the animals had significant anti-Ad4 antibody titers (reciprocal titers, >4) ( Chimpanzees received primary oral immunizations with Ad7 or Wy-Ad7HZ6-1 followed 11 weeks later by oral booster vaccinations with Wy-Ad4HHxHS as indicated in Table 2 . The chimpanzees remained healthy throughout the 2-week (Fig. 2) . Anti-Ad7 titers persisted at high levels throughout the remainder ofthe study (11 months) for all three chimpanzees. Each of the three chimpanzees experienced significant anti-Ad4 neutralizing antibody responses (reciprocal titers, 64) within 3 weeks of booster immunizations with Wy-Ad4HHxHS (Fig. 2) . Anti-Ad4 neutralizing antibody titers peaked at -2 months and remained elevated throughout the experiment.
After primary immunization with Wy-Ad7HZ6-1, chimpanzee 1374 developed a transient seroresponse to HBsAg, which peaked at 9 mIU during the fifth week postinoculation. The anti-HBs response then declined during the following 2-week period. Chimpanzee 1373, which was also vaccinated with Wy-Ad7HZ6-1, did not mount a detectable anti-HBs response. Following booster immunizations of chimpanzees 1373 and 1374 with Wy-Ad4HHxHS, secondary anti-HBs responses were elicited. The anti-HBs booster responses developed more rapidly, persisted for longer periods, and peaked at higher levels (Fig. 3) HBV Challenge. Eight weeks after booster immunizations, chimpanzees 1373, 1374, and 1375, as well as a control chimpanzee (no. 1376), were challenged with 10i-O chimpanzee infectious doses of heterologous HBV (ayw strain). Ten weeks after challenge, the control chimpanzee (no. 1376) experienced an acute HBV infection. HBsAg was detected in the blood of this animal for an 11-week period and elevated serum levels of liver enzymes followed a course typical for an acute HBV infection (Fig. 3) . Anti-HBc and anti-HBs re- .1000 800 Chimpanzee 1373, which also possessed an anti-HBs serum titer of 9 mIU at the time of HBV challenge, also developed a subclinical HBV infection. Low levels of HBsAg were detected in the serum of this animal for a brief 2-week period starting at 9 weeks postchallenge. However, no elevation in liver enzyme levels was observed in this animal. Immediately after the transient antigenemia, a large anti-HBs response developed. This response had not yet peaked at the time the experiment was terminated and was also of the IgG isotype (data not shown). An anti-HBc antibody response developed 11 weeks postchallenge.
Chimpanzee 1375, which did not develop a detectable anti-HBs response following vaccination with Wy-Ad4-HHxHS, was not protected from clinical hepatitis following HBV challenge. Chimpanzee 1374, which experienced the highest anti-HBs response after dual vaccination and which had a titer of9 mIU at the time of HBV challenge, did not develop clinical hepatitis. HBsAg was not detected in the blood of this chimpanzee and liver transaminase levels were normal throughout the 6-month observation period following challenge. However, 17 weeks postchallenge, a strong anti-HBs response developed as well as a slight but significant antiHBc response. This increase, which ranged from 2.4 to 3.5 negative/positive units from weeks 36-43, is not apparent in Fig. 3 A recent study of adenovirus mutants that have lost the ability to block expression of class I major histocompatibility antigens via deletion of sequences encoding gpl9K has indicated that such mutants show increased capacity for induction of lung pathology and disease in cotton rats (30) . In the present study, Wy-Ad7HZ6-1, which contains a deletion of the coding sequence for gpl9K, did not cause enteric disease in chimpanzees.
With regard to the use of heterotypic vectors for booster applications, it should be noted that 42 antigenically distinct adenovirus serotypes have been described (31) . A large proportion of these viruses have not been linked to disease states in humans and on that basis might be considered for use as vectors for vaccine applications. This diversity of serotypes could also be used to overcome problems ofpreexisting adenovirus immunity in vaccine recipients.
A seroprevalence study of chimpanzees at Sema indicated substantial preexisting immunity to Ad4 but not to Ad7. This antibody profile is consistent with both the known antigenic cross-reactivity between the chimpanzee adenovirus Pan 9 and human Ad4 as well as the demonstrated absence of antigenic relatedness between chimpanzee adenoviruses and human Ad7 (17) . A similar seroprevalence study of chimpanzees housed at Buckshire (Perkasie, PA) indicated that 100%o (10/10) of the animals tested were seropositive for Ad4 and 90%o (9/10) were seropositive for Ad7 (unpublished data). The factors contributing to these differences in antibody profiles between chimpanzee groups are not known but may be related to differences in conditions under which the chimpanzees were maintained. Chimpanzees at Sema were housed in individual isolators, whereas the chimpanzees at Buckshire were not housed under isolator conditions. Isolation of the chimpanzees may have contributed to protection of the animals from contact with human adenoviruses or adenoviruses from other chimpanzees.
In summary, we have identified the chimpanzee as a model for testing Ad7-and Ad4-vectored vaccines and demonstrated the feasibility of using oral enteric vaccination with recombinant adenoviruses to induce humoral immune responses to foreign viral genes. This approach to vaccination may be adapted for immunization against many different diseases.
